Thanks Kens, I wish we could get out hands on these sorts of...

Thanks Kens, I wish we could get out hands on these sorts of reports without paying so much but in reality i suspect they are outdated as soon as they are written. I cant imagine it talks in detail to the current position the FDA has on abuse deterrents and their effect on the market. Thus any discussions they have on the opioid market as a whole will be ambiguous. Too many unknowns in a time of much change.

Hottod, thanks for your kind comments. I agree with your comments and cant add any more at the minute. Lets see what happens in March.

Just in case you didn't see this, yesterday the FDA released their guidance for abuse deterrent opioid manufacturers. It outlines the means of proving an opioids abuse deterrent technology meets its goal of actually limiting abuse. Something to keep track of and ensure future trials capture enough data to meet the expectations set out in this guidance... which im sure a patch can do with ease. No issues here, just information.

Press release:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm334785.htm

The Guidance document:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf